GlaxoSmithKline, King of Prussia, PA, USA Stimulation by CD40 ligand (L) improves B-cell malignancy immunogenicity, and also induces proliferative signals. To avoid these tumorigenic effects, we studied an alternate way of tumor-cell stimulation by homologous to lymphotoxin, inducible expression, competing for GpD of herpesvirus, which binds to the herpesvirus entry mediator (HVEM), and is expressed on T-lymphocytes (LIGHT), the ligand for HVEM, a new member of the tumor necrosis factor (TNF)/TNF-receptor (-R) family. HVEM is constitutively expressed on the surface of tumor B cells. We focused our attention on mantle cell lymphoma, a subtype of Bcell malignancy of poor prognosis. Triggering by LIGHT, in contrast to CD40L stimulation, did not increase lymphoma proliferation nor decrease chemotherapy entrance. We observed an upregulation of the TNFR apoptosis-inducing ligand Fas, and in contrast to CD40L-induced protection, an enhancement of lymphoma sensitivity to Fas-induced apoptosis. LIGHT triggering increased lymphoma cell recognition in a mixed lymphocyte response. In conclusion, LIGHT-mediated triggering renders B-cell lymphomas more immunogeneic and sensitive to apoptosis, without inducing proliferation. Since LIGHT triggering also enhances the functions of T-lymphocytes and dendritic cells, it could be a unique way to restore an efficient cancer control by its pleiotropic effects on immune effectors and tumor cells.
Introduction
Most human malignancies express tumor-associated or tumorspecific antigens (Ags), but do not elicit an efficient immune response. 1 This could be rectified by increasing the presentation of exogenously processed tumor Ags by professional antigenpresenting cells (APCs), such as dendritic cells. 2 Alternatively, the APC functions of cancer cells can be directly enhanced, thus improving both the presentation of endogenous peptides and the costimulation signals that they provide to T cells. The role of CD40 and its ligand (CD40L) in the modulation of tumor cell APC functions has been underlined more particularly with regard to B cells. 3 The CD40 stimulation of tumor cells could be of major importance in eliciting an efficient antitumor effect, since it both improves the initial phase of the immune response (Ag recognition) and the effector stage (cytotoxicity/cytokine secretion) via adhesion/costimulatory molecule upregulation, increased endogenous Ag presentation and cytokine secretion, or by mimicking T-lymphocyte CD40L signaling. 4 These data could support the use of CD40-mediated tumor-cell stimulation for adoptive transfer immunotherapy. 5 Nonetheless, it must be noted that the antitumor effects in lymphoid neoplasms, which is in part due to adhesion/costimulation molecule upregulation, 6 ,7 could in part be counterbalanced by the proliferative potential of CD40 triggering, since antiapoptotic and growth signals are delivered via CD40 triggering more particularly in low-grade B-cell malignancies. 8 This putative tumorigenic effect of CD40 triggering prompted us to analyze other ways to improve the immunogenicity of lymphoid tumors.
As an alternative to CD40 stimulation, we chose to focus our study on the herpes simplex (HSV) virus entry mediator molecule (HVEM, or TNF-SuperFamily14), [9] [10] [11] a new member of the TNF receptor (TNF-R) superfamily that can mediate tumor apoptosis, 12 but was first identified 9 for its property of mediating the entry of HSV. The tissue distribution of HVEM is wide, showing expression in primary cells in the lung, spleen, thymus, monocytes, B-lymphocytes and T-lymphocytes. 10, 11, 13 Many solid tumor cell lines do not express HVEM, while hematopoietic cell lines, in particular, of myelomonocytic lineage, express the specific mRNA that is further upregulated by phorbol esters. 10 To date, three ligands have been identified for HVEM. The first one is the herpes simplex virus surface envelope glycoprotein gD. 9 The other two are members of the TNF/TNFR family; the trimeric lymphotoxin a (LTa3) and LIGHT (TL4 or TNF-ReceptorSF14), a 29 kDa type II transmembrane protein produced by activated T cells. 14 We studied the expression, regulation and function of HVEM in a B-cell lymphoid malignancies of bad prognosis, the mantle cell lymphoma (MCL), in order to determine if it could be a good candidate for antitumor immunotherapy approaches.
Materials and methods
Blood samples, cell separation and cell lines MCL diagnosis was established mainly by immunophenotype (surface IgM, expression, search for k or l chain expression, positivity for pan-B Ags (CD19, 20, 22 and 24) and HLA-DR Ags, positivity for the pan-T-cell Ag CD5 together with negativity for CD10 and CD23 Ags). Diagnosis was then confirmed by the presence of the characteristic cytogenetic abnormality, that is, t(11;14)(q13;q32) or variant translocations. In order to have sufficient number of tumor cells, six patients with circulating lymphoma cells representing X95% of mononucleated cells were selected. Isolation of tumor cells was performed on Ficoll-Hypaque gradients 15 and controlled by flow-cytometry analysis. Peripheral normal blood mononucleated cells (PBMCs) of healthy donors were isolated on Ficoll-Hypaque gradients. 15 The T-lymphocytes were isolated as the CD2-positive PBMC population, corresponding to cells that adhere to sheep erythrocytes 16 in E-rosetting technique, but failed to adhere to plastic dishes after overnight incubation in medium þ 30% FCS. The CD4 þ T cells were isolated by two rounds of negative selection using magnetic beads (Beckman Coulter, France) coated with anti-CD4 (13B8.2, D Olive) or anti-CD8 (8E17, D Olive) mAbs. The purity of CD4 þ cells was evaluated by flow-cytometry analysis and was in all cases X95%. The U266BL and XG7 (plasma cell lines), Daudi and Raji (Burkitt's lymphoma), DEL (Hodgkin's lymphoma) cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA).
CD154/CD40L-and LIGHT-transfected cell lines
Full-length cDNA of human CD154/CD40L and human LIGHT were cloned in pcDNA3.1/Neo and pcDNA3.1/Hygro (Invitrogen, Groningen, The Netherlands), respectively, and transfected by electroporation (960 mF, 220 V) in Ltk murine fibroblasts. Stably transfected cells, selected by resistance to geneticin (Life Technologies, Rockville, MD, USA) or hygromycin B (Invitrogen), were selected by three rounds of FACS sorting. CD32-transfected fibroblasts were a kind gift from Schering-Plough (Dardilly, France). As a LIGHT specificity control, we used at least one time for each type of experiment neutralizing LIGHT mAb 2C8 or recombinant HVEM-Fc, added at 5 mg/ml at the start of the culture. In all cases, the results were not different from CD32 control transfectants, and thus are not further detailed in the results section.
Culture conditions and primary mixed lymphocyte reaction (MLR)
For lymphoma proliferation, culture experiments were performed in RPMI 1640 (Bioproducts, MA, USA) with 10% fetal bovine serum (Bioproducts). T-lymphocytes were cultured at 10 6 /ml. For MHC-unmatched MLR against lymphoma cells, responding CD4
þ T lymphocytes were isolated from three unrelated healthy blood donors as described previously. Culture experiments were performed in RPMI 1640 (Bioproducts) with 10% fetal bovine serum (Bioproducts), 1% L-glutamine (Life Technologies, Gaithersburg, MA, USA), 1% Na pyruvate (Life Technologies) and 5 Â 10 À5 ml b-mercaptoethanol (Sigma Chemical Co, St Louis, MO, USA). When indicated, g-interferon (g-IFN) was used at 1 ng/ml (Roche, Bazel, Switzerland). Lymphoma cells had g-irradiation at 50 Gy, were then incubated (from 5 Â 10 4 per well) with T-lymphocytes (5 Â 10 4 per well) for 6 days and pulsed for the last 14 hours with [ /ml) to lymphoma cells (1 Â 10 6 /ml). To induce Fas-dependent apoptosis, we used the CH-11 anti-Fas (Immunotech) mAb at 125 ng/ml, a concentration (as per the manufacturer's recommendation) corresponding to 90% death of the WR19L-12a Fas-transfected cell line. Counting of dead cells was performed using the Trypan blue exclusion (0.4% solution, Sigma, St Louis, MO, USA) technique.
Flow-cytometry studies
Cells were processed following standard procedures and analysis was performed on an FacScan flow cytometer (Becton Dickinson, Immunocytometry Systems, CA, USA). The following mAbs were used: the anti-HVEM 12C5 and 20D4 (mouse IgG1, SmithKline Beecham), anti-CD3, anti-CD4, anti-CD8, anti-CD14, anti-CD19 (Beckman Coulter), anti-CD80, anti-CD54, anti-CD58 (Beckton Dickinson), anti-CD86, anti-CD40L and anti-Fas (Pharmingen). Apoptosis was detected using the APO2.7 mAb (Immunotech), an early marker of apoptosis that recognizes a 38 kDa protein localized on the membrane of mitochondria whose expression appears to be restricted to cells undergoing programmed cell death. For propidium iodide (PI) cell-cycle analysis, cell suspensions were washed in phosphatebuffered saline (PBS), resuspended in 0.1% sodium citrate, 0.1% Triton X-100 and 50 mg/ml PI, and stored for 24 h at 41C. After centrifugation, the cells were resuspended in PBS containing 250 mg/ml RNAse. Monovariate distributions of cell number vs DNA content (PI) were analyzed using an excitation at 488 nm and PI fluorescence intensity was recorded through a 575-nm filter. At least 20 000 events were collected in each final gated histogram.
Nucleic acid preparation, RT-PCR amplification and primers
Briefly, total RNA was isolated from 0.1 to 0.5 Â 10 6 cells for each sample, which was suspended in Trizol (GIBCO-BRL, France), and extracted by phenol-chloroform, as recommended by the manufacturer. The RT was performed using standard procedures using MMLV Superscript reverse transcriptase and random hexamers according to the manufacturer's instructions (Life Science, USA). For PCR, 2.5 ml of this cDNA was used as the target in a total volume of 25 ml containing 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl pH 8.5, 200 mM each of dNTP, 1 pmol/ml of primers and 1.25 U of Taq polymerase (Perkin-Elmer). The amplification was performed in a Touchdown Temperature Cycling System thermal cycler (Hybaid, Teddington, UK); the first cycle 941C for 3 min, then annealing at 651C for 30 s, extension at 721C for 30 s and then denaturation at 941C for 30 s (25 cycles for b-actin, 30 cycles for DR6), terminating for 10 min at 721C. The detection of the housekeeping gene b-actin was used to assess RT and PCR efficiency, with the following primers: sense (S), 5 0 -GGC ATC GTG ATG GAC TCC G-3 0 ; and the antisense (AS), 5 0 -GCT GGA AGG TGG ACA GCG A-3'. The oligonucleotides used for the Homo sapiens TNFR-related death receptor6 (DR6) were S, 5 0 -TGC CAG TGA GAG GGA GGT TG-3 0 ; and AS, 5 0 -GGA GCC GCT GGA TGT AGA GT-3 0 . Half of the RT-PCR product was run on a 1.5% agarose gel, and the molecular weights of migrating products were evaluated in comparison with fX 174 RF DNA HaeII fragments.
Drug accumulation
The study was performed as previously described by Feller et al. 17 Briefly, lymphoma cells (1 Â 10 6 ) were incubated at 371C in 2 mM DNR (Sigma). The fluorescence was then analyzed at different incubation times, the influx being stopped by washing the cells with ice-cold medium. Nonspecific binding of DNR was evaluated by adding an ice-cold drug-containing medium to the cells and washing them immediately. The daunorubicin (DNR) intracellular detection was based on the intrinsic fluorescence of DNR labeling. For DNR detection, we used a laser excitation of 488 nm, while fluorescence was collected through a 575 nm filter.
Cytokine production and assay T-lymphocytes were incubated with lymphoma cells in RPMI 1640 (Bioproducts, MA, USA) with 10% fetal bovine serum, and the supernatants were harvested after a 4-day incubation. The IL-2 was measured using an immunoenzymatic assay with a sensitivity of 5 pg/ml (Immunotech). (Table 1 and Figure 1) We studied HVEM baseline expression in a panel of lymphoid cells. The expression of HVEM was constant in normal Blymphocytes ( Figure 1a and Table 1 ). As seen in Table 1 , HVEM was not expressed in the two plasma cell lines that we evaluated (U266BL and XG7), although it was expressed in all myeloma primary cells and in plasma cell leukemias. All the Epstein-Barr virus (EBV) cell lines derived from healthy blood donors expressed HVEM, while HVEM expression on Burkitt's lymphoma depended on the cell line tested, since it was positive on Raji cells, but not on Daudi. We failed to detect HVEM on the Hodgkin cell line we tested. The expression of HVEM was constant in chronic lymphocytic leukemias (CLL), often observed in acute lymphoblastic leukemia (ALL) and in all the MCL we tested. In all the lymphoid cells tested, we failed to detect LIGHT expression (data not shown). We chose to focus our study on MCL, since it represents a lymphoid malignancy with a very poor short-term prognosis in the absence of an actual curative therapy.
Results

Expression of HVEM in lymphoid cells
Analysis of lymphoma cells following stimulation via CD40 or LIGHT: proliferation, cell-cycle and chemotherapy entrance ( Figure 2 and Table 2) We tested two pivotal parameters involved in tumor eradication; proliferation of tumor cells and entrance of chemotherapy drugs. As seen in Figure 2a , lymphoma cells stimulated by CD40L-transfected cells displayed a high-level proliferation. In sharp contrast, stimulation by LIGHT-transfected cells did not induce any proliferation (even with a higher level of stimulating cells, that is, 50 000/wells, which corresponds to a 1/1 ratio, data not shown). We checked the cell cycle using the PI technique (Table 2 ). No significant difference was observed either regarding the apoptotic cells or cells in the G0/G1 or S/G2/M phases between the control CD32 and LIGHT conditions. In contrast, CD40L stimulation, in line with data from the literature, induced MCL to proliferate as measured by increased fraction of cells in the S/M phase 18 , and also decreased apoptosis (in contrast to data obtained with soluble CD40L 18 ). We then tested the entrance of a pivotal drug used in lymphoma treatment, that is, DNR (Figure 2b ). While no differences in drug entrance was observed after 5 min, after 15 min the entrance of DNR was significantly higher (Po0.05) in the CD32 and LIGHT conditions (5.772 and 8.773%, respectively), than in the CD40L condition (1.871%).
Effect of LIGHT stimulation of lymphoma cells on adhesion/costimulatory molecules and apoptosisinducing ligands expression ( Figure 3 )
In order to better define the effects of HVEM triggering, we analyzed the surface phenotype of lymphoma cells after a 48-h incubation with CD32-, CD40L-or LIGHT-transfected L cells (Figure 3a) . The stimulation of lymphoma cells by LIGHT failed to upregulate CD80, CD54 and CD58, but we observed an increase in CD86 and Fas expression compared to the CD32-stimulated cells. The CD40L triggering induced a more important increase of CD80, CD86 and Fas than LIGHT stimulation, with also an increased expression of CD54 and CD58. Following the observation of Fas upregulation, we investigated the regulation of other apoptosisinducing TNFR family members using RT-PCR (Figure 3b ). In comparison with control CD32-transfected cell incubation, we detected an increase in the specific DR6 mRNA in all the five lymphomas tested following either CD40L-or LIGHT-transfected cells. We failed to detect a systematized regulation of the other apoptosis-inducing TNFR family members that we tested by RT-PCR, that is, DR3, DR4, DR5 and TNFR1 (data not shown). Data are presented as the % positive blasts or MFI after background subtraction. Samples that were found to contain less than 5% blast or had an MFI o5 were defined as negative (À). For positive samples, the mean % of positive cells was as follows: 5-10%, 7; 10-20%, +; 20-50%, ++, 450%, +++. The MFI was as follows: 5-10, 7; 410-20, +; 420-100, ++; 4100, +++; one out of the seven AML tested expressed HVEM with high intensity (+++/++).
Sensitivity of lymphoma cells to Fas-induced apoptosis and death (Figure 4).
We assessed the correlation of Fas expression with Fas-induced apoptosis using the anti-Fas mAb CH-11 at a concentration (as per the manufacturer's recommendation) expected to induce significant apoptosis (Figure 4a ). The detection of apoptotic cells was performed using the APO2.7 surface expression, which is restricted to cells undergoing apoptosis. At 2 h after thawing, less than 10% lymphoma cells were labeled by APO2.7 mAb (data not shown). After 48 h of culture in standard medium without cytokine addition, the percentage of apoptotic cells was checked. The lymphoma cells incubated with CD32-transfected cells that underwent apoptosis were 1874% in medium alone and 4677% when anti-Fas mAb was added. When CD40L-transfected cells were used for cocultures, only 473% cells underwent spontaneous apoptosis and 3877% when anti-Fas mAb was added. When LIGHT-transfected cells were used for coculture, the percentage of spontaneous apoptotic cells (2074%) was comparable to the CD32 control condition. In contrast, following the addition of anti-Fas mAb, 7078% cells underwent apoptosis, a percentage significantly higher (Po0.05) than in the CD32 and CD40L conditions. We verified Evaluation of cell cycle was performed using the PI technique, as described in Materials and methods. the effect of LIGHT stimulation on cell viability using the trypan blue exclusion technique (Figure 4b) . These experiments confirmed the well-known protection from cell death observed following CD40L incubation, while in contrast preincubation of lymphoma cells with LIGHT-expressing transfectants failed to induce per se lymphoma cell death, but significantly increased Fas-induced cell death in comparison with CD32 control transfected cells (after 72 h of culture, 5375% for CD32 condition vs 8179% for the LIGHT condition).
Proliferation and IL-2 secretion of CD4
þ T-lymphocytes in allogeneic mixed lymphocyte response against lymphoma cells ( Figure 5) We tested the modulation of lymphoma cell immunogenicity induced by LIGHT triggering. As seen in Figure 5a , stimulation of lymphoma cells via HVEM induced greater proliferation of responding CD4 þ T-lymphocytes than incubation with medium alone, CD32-expressing control fibroblast or IFN-g. Of note, the addition of IFN-g in conjunction with LIGHT stimulation did not have any synergistic or even additive effect. With respect to IL-2 secretion (Figure 5b) , prestimulation of lymphoma cells via HVEM allowed a relevant secretion by responding lymphocytes (E250 pgml/250 000 cells/ml), higher than the level obtained by lymphoma cell preincubation with medium alone, CD32-expressing control fibroblast or even g-IFN (o60 pgml). We failed to observe a synergistic or additive effect by the addition of g-IFN to HVEM stimulation.
Discussion
Primary Ag-specific T-cell response requires not only Ag presentation but also costimulatory signals delivered by APCs, in particular, via the CD28-CD80/CD86 pathway, in order to obtain effective T-cell immunity instead of alloAg-specific Effect of LIGHT stimulation of lymphoma cells on adhesion/costimulatory molecules and apoptosis-inducing ligand expression. In (a), lymphoma cells were incubated with negative control CD32-(black bars), CD40L-(stripped bars) or LIGHTtransfected (white bars), and analyzed after 48 h by flow cytometry using specific antibodies. The results are expressed here as % of positive cells (after subtraction of the background corresponding to the isotype-matched control). This is one representative experiment out of three performed with different lymphomas. In (b), the expression of the TNFR-related death receptor-6 (DR6) mRNA (upper row) was evaluated by RT-PCR analysis in lymphoma cells stimulated by control CD32-, CD40L-or LIGHT-transfected fibroblasts. The b-actin (lower row) was used as control of mRNA quality and as a quantitative standard for mRNA comparison. This RT-PCR is one representative experiment out of five performed with different lymphomas.
Figure 4
Sensitivity of lymphoma cells to fas-induced apoptosis and death. In (a), lymphoma cells were incubated with CD32-(first row), CD40L-(second row) or LIGHT-transfected (third row) cells in the absence (left column) or presence (right column) of an anti-Fas mAb with proapoptotic effect. Apoptosis was evaluated using flowcytometry analysis with the Apo2.7 mAb (black histogram), and data are presented as %/MFI after subtraction of the background corresponding to the isotypic control (white histograms). Data correspond to one representative experiment out of three performed. In (b), lymphoma cells were incubated with CD32-, CD40L-or LIGHTtransfected cells in the absence or presence of the anti-Fas mAb and analyzed at T0 (black bars), after 24-h (stripped bars) or 72-h (white bars) incubation. Cell death was evaluated using trypan blue exclusion. Data correspond to the mean7s.d. of three independent experiments performed in triplicate, and 200 cells were counted for each experimental point.
anergy. [19] [20] One proposed model to improve the immunogenicity of B-cell lymphomas 21 or CLL 6 relies on tumor cell triggering via CD40 that repairs the defect in costimulation by upregulating CD58/LFA-3, CD54/ICAM-1 and CD80/CD86 molecules. Our data demonstrate that HVEM is expressed on all normal B cells and in 'low-grade' lymphoma cells or CLL. This expression is long lasting, even when lymphoma cells are stimulated (data not shown), in contrast to T-lymphocytes that downregulate HVEM expression following stimulation. 13 The stimulation of lymphoma cells via HVEM induced an increased expression of CD86, but not of CD80. Experimental data support a greater role for CD86 than CD80 in conventional allogeneic MLR, 22 one-way MLR against dendritic cells, 23 lymphoma 24 or acute myeloid leukemia. 25 This predominant effect of CD86 expression can explain the improved in vitro allogeneic immune recognition that we observed following stimulation of lymphoma cells via HVEM.
Although lymphoma stimulation is an interesting model to improve tumor immunogenicity, in most low-grade lymphoid malignancies and Hodgkin's disease, in vitro stimulation via the CD40 pathway results in tumor cell proliferation and/or protection against apoptosis. 8 This proliferative effect has also been demonstrated in MCL. 18 These effects partially mimic those observed in normal B cells. 26, 27 The CD40 system appears to be very interesting for an ex vivo approach of immunotherapy, that is, in vitro treatment of irradiated tumor cells that are subsequently reinfused to the patient, but raises problems for a direct in vivo use of anti-CD40 therapy. The intracellular signaling delivered via HVEM, which does not contain intracellular death domain, involves TRAF 1, 2, 3 and 5, and is able to activate NF-kB. 28 In the system described in this paper, stimulation via HVEM failed to induce any lymphoma proliferation, even in the presence of cytokines such as IL-4 (data not shown), in sharp contrast to the CD40/CD40L system. With respect to apoptosis, some data in solid tumors suggest that, despite the absence of a death domain, stimulation via HVEM in conjunction with IFN-g induces programmed cell death. 15 We failed to observe any induction (or decrease) of MCL apoptosis by LIGHT treatment, even in association with IFN-g (data not shown). Of note, LIGHT stimulation increased Fas expression in comparison with control conditions. A parallelism between Fas expression and sensitivity to Fas-induced apoptosis is not always observed in lymphoid malignancies. 29, 30 Nonetheless, we observed that the upregulation of Fas expression correlated, to some extent, with Fas-induced apoptosis sensitivity of lymphoma cells. This suggests that LIGHT stimulation partially reversed the resistance to Fas killing. Since both immune killing and chemotherapy sensitivity partially rely on apoptosis and more specifically on Fas-driven killing, [31] [32] [33] LIGHT stimulation of lymphoma cells could be a way to improve tumor cell eradication, in contrast to CD40 stimulation, which can protect lymphoma cells from both spontaneous and chemotherapy-induced apoptosis. 8 Regarding the interference of LIGHT or CD40L triggering with chemotherapy effects, we observed that the accumulation of DNR was not modified by LIGHT when compared to the control condition. In contrast, the lower levels of DNR in CD40L-stimulated tumor cells suggest that this triggering may increase drug efflux, putatively via multidrug resistance gene activation. This hypothesis is under investigation. We completed the study of TNF family apoptosisinducing receptor by checking the regulation of DR6, following LIGHT stimulation. DR6 is a TNFR member that interacts with the TNFR-associated death domain protein (TRADD) and induces apoptosis. 34 The demonstration of DR6 role in the activation and function of B cells is quite recent. 35 In mice, DR6 is downregulated upon B-cell activation, and plays a role in B-cell survival since its targeted disruption decrease apoptosis while increasing cell proliferation. 35 Interestingly, in contrast to normal B cells from mice, we observed an upregulation of DR6 mRNA following CD40L or LIGHT stimulation of MCL. Since the ligand for DR6, to our knowledge, has not yet been identified, we were not able to measure MCL sensitivity to DR6-induced apoptosis, which is nonetheless likely to be increased more particularly by LIGHT triggering that, in contrast to CD40L stimulation, does not deliver antiapoptotic signals.
In conclusion, our data suggest that stimulation of lymphoma cells by LIGHT retains the immune restoration capacities, without the proliferation-inducing or antiapoptotic effects of CD40L triggering. In addition, LIGHT triggering efficiently upregulated the sensitivity of lymphoma cells to Fas-induced apoptosis. Finally, in vivo, LIGHT stimulation would also be expected to amplify other pivotal pathways of the immune network, since LIGHT costimulates CD3-induced T-cell proliferation, 12, 36 participates in dendritic cell maturation 37 and potently amplifies IL-12 secretion. 37 These data make LIGHT stimulation a good candidate for a 'pleiotropic immune therapy' approach that simultaneously (1) restores intrinsic tumor immunogenicity, (2) enhances tumour sensitivity to apoptosis, (3) participates in dendritic cell functional maturation, (4) directly stimulates T-lymphocyte activation and (5) indirectly Proliferation and IL-2 secretion of CD4 þ T-lymphocytes in allogeneic MLR against lymphoma cells. Allogeneic purified CD4 þ lymphocytes were incubated at a 1/1 ratio with irradiated lymphoma cells preincubated for 48 h in different conditions. In (a), the proliferation of responding T-lymphocytes was assessed after 6 days of culture by an [H 3 ]thymidine pulse in the last 14 h of culture. Data represent the mean7s.d. of triplicates, and the experiments were performed with two different normal lymphocyte donors with two different lymphomas. In (b), the secretion of IL-2 by responding Tlymphocytes was assessed after 4 days of culture by an ELISA assay. Data represent the mean7s.d. of duplicates, and the experiments were performed with two different normal lymphocyte donors with two different lymphomas.
enhances T-lymphocyte cytotoxicity potential via amplification of dendritic cell IL-12 secretion.
